10-QPeriod: Q2 FY2025

MCKESSON CORP Quarterly Report for Q2 Ended Sep 30, 2024

Filed November 7, 2024For Securities:MCK

Summary

McKesson Corporation reported its financial results for the second quarter and first half of fiscal year 2025. Total revenues saw a significant increase of 21% for the quarter and 14% for the six-month period, driven by growth in the U.S. Pharmaceutical segment and increased pharmaceutical distribution volumes internationally. However, diluted earnings per share decreased substantially, reflecting higher operating expenses and specific charges. Key items impacting the results include a substantial charge of $643 million related to the remeasurement of the Canadian retail disposal group to fair value less costs to sell. Additionally, the company incurred $227 million in restructuring charges for enterprise-wide technology modernization initiatives. The company also continues to manage its significant estimated liability for opioid-related claims, totaling $6.4 billion as of period end. Despite the earnings decline, McKesson demonstrated strong operational cash flow and continued to return capital to shareholders through share repurchases ($2.0 billion in the first half) and a raised quarterly dividend. The company also announced a significant acquisition in the oncology sector, pending regulatory approval.

Financial Highlights

52 data points
Beta

Revenue

$93.65B

3.5% Gross Margin

Net Income

$241.00M

0.3% Net Margin

EPS (Diluted)

$1.87

Total Assets

$72.43B

Cash & Equivalents

$2.51B

Free Cash Flow

$1.96B

Financial Statements
Beta
Revenue$93.65B
Cost of Revenue$90.40B
Gross Profit$3.25B
SG&A Expenses$2.50B
Operating Expenses$2.67B
Operating Income$578.00M
Interest Expense$78.00M
Net Income$241.00M
EPS (Basic)$1.88
EPS (Diluted)$1.87
Shares Outstanding (Basic)128.70M
Shares Outstanding (Diluted)129.30M

Key Highlights

  • 1Revenue increased by 21% year-over-year to $93.7 billion for the quarter and 14% to $172.9 billion for the six months, primarily driven by the U.S. Pharmaceutical segment and international operations.
  • 2Diluted earnings per share declined significantly to $1.87 for the quarter (down from $4.92) and $8.89 for the six months (down from $11.95), reflecting higher operating expenses and specific charges.
  • 3The company recorded a $643 million charge related to the remeasurement of its Canadian retail disposal group to fair value less costs to sell.
  • 4Restructuring charges of $227 million were recognized for enterprise-wide initiatives to modernize technology and improve operating efficiency.
  • 5McKesson announced a definitive agreement to acquire a 70% controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures) for approximately $2.49 billion.
  • 6The company returned $2.2 billion to shareholders through $2.0 billion in stock repurchases and $162 million in dividends during the first half of the fiscal year.
  • 7The total estimated liability for opioid-related claims stands at $6.4 billion as of September 30, 2024.

Frequently Asked Questions

McKesson's revenue growth is primarily driven by market expansion in its U.S. Pharmaceutical segment, with higher volumes from retail national account customers and growth in specialty pharmaceuticals. International operations also contributed with increased pharmaceutical distribution volumes.

The decrease in diluted earnings per share is largely attributable to a substantial charge of $643 million related to the remeasurement of the Canadian retail disposal group to fair value less costs to sell. Additionally, restructuring charges totaling $227 million for technology modernization initiatives and higher overall operating expenses impacted profitability.

McKesson continues to face opioid-related litigation. The company has an estimated total liability of $6.4 billion as of September 30, 2024, which includes amounts for settlements with states, subdivisions, Native American tribes, acute care hospitals, and third-party payors. The company believes it has valid defenses for claims not covered by settlements.

McKesson actively returns capital to shareholders through its share repurchase program and dividend payments. In the first half of fiscal year 2025, the company repurchased $2.0 billion of its common stock and paid $162 million in dividends. The quarterly dividend was also raised to $0.71 per share.